DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose ...

Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...

A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to update the app.

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

With more than 10 years of pioneering CGM market leadership in AID integration, Dexcom is the most studied CGM brand with AID capabilities and the clear choice for powering AID systems 3,4 The ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM ...

DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 ...

LONDON--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

If you are a new investor, healthcare stocks can provide numerous diversification benefits to your portfolio and help enhance ...

According to Diabète Québec, type 2 diabetes is the most common form, affecting nearly 90% of those living with diabetes, and many eventually require insulin when lifestyle changes and oral ...